الصفحة الرئيسية>>Lipids>> Glycerophospholipids>>DMABA NHS ester

DMABA NHS ester (Synonyms: 4(dimethylamino) Benzoic Acid, DMABA Nhydroxysuccinimide ester, NSuccinimidyl 4(dimethylamino)benzoate)

رقم الكتالوجGC43499

Phosphatidylethanolamine (PE) lipids are important components of cell membranes and biochemical pathways of fatty acid synthesis that contain abundant polyunsaturated fatty acyl (PUFA) groups.

Products are for research use only. Not for human use. We do not sell to patients.

DMABA NHS ester التركيب الكيميائي

Cas No.: 58068-85-2

الحجم السعر المخزون الكميّة
50mg
49٫00
متوفر
100mg
94٫00
متوفر
500mg
398٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Phosphatidylethanolamine (PE) lipids are important components of cell membranes and biochemical pathways of fatty acid synthesis that contain abundant polyunsaturated fatty acyl (PUFA) groups. Oxidation of these phospholipids may be linked to various human diseases. DMABA NHS ester is a reagent that reacts with the primary amine group of PE lipids. This facilitates the use of electrospray tandem mass spectrometry for the detection of diacyl, ether, and plasmalogen PE lipids that cannot be readily observed otherwise. DMABA NHS ester has been used in combination with DMABA NHS ester-d4, -d6, and -d10 to study relative changes in PE lipid abundance before and after radical oxidation.

مراجعات

Review for DMABA NHS ester

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DMABA NHS ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.